Subjects n | 74 | 106 | |
Age years | 66±9 | 67±8 | 0.745 |
Female sex n (%) | 31 (42) | 68 (64) | <0.01 |
BMI kg·m−2 | 26.0±6.2 | 26.4±5.8 | 0.146 |
Smoking status | | | 0.318 |
Former smoker | 48 (65) | 76 (72) | |
Current smoker | 26 (35) | 30 (28) | |
Tobacco exposure pack-years | 50 (40–59) | 43 (34–53) | 0.141 |
Country | 0.867 |
Denmark | 51 (69) | 75 (71) | |
Sweden | 23 (31) | 31 (29) | |
SNOT22 (total score) | 29 (23–37) | 14 (9–22) | <0.001 |
SNOT22nasal | 10 (8–13) | 2 (0–4) | |
Sleep and productivity sub-score (q13–19) | 12 (7–18) | 8 (3–13) | <0.001 |
CAT score | 17.4±7.5 | 14.9±6.5 | <0.05 |
Inhaled medication | |
ICS use | 31 (42) | 47 (44) | 0.701 |
Dual bronchodilator | 23 (31) | 26 (25) | 0.408 |
Triple therapy | 27 (37) | 39 (37) | 0.843 |
FEV1 L | 1.48±0.59 | 1.31±0.53 | <0.05 |
FEV1 % pred | 53±16 | 52±17 | 0.629 |
FVC L | 2.96±0.97 | 2.67±0.88 | <0.05 |
FVC % pred | 82 ±17 | 84±19 | 0.403 |
RV L | 4.39±1.43 | 4.50±1.44 | 0.666 |
RV % pred | 190±64 | 202±63 | 0.284 |
TLC L | 7.20±1.66 | 6.90±1.53 | 0.235 |
TLC % pred | 116±23 | 121±22 | 0.281 |
DLCO mmol·min−1·kPa−1 | 4.40±1.93 | 3.89±1.59 | 0.103 |
DLCO % pred | 52±21 | 48±17 | 0.249 |
ΔFEV1 mL | 110±132 | 108±126 | 0.905 |
ΔFEV1 % | 10±12 | 10±12 | 0.947 |
Bronchodilator response >12%+200 mL | 13 (17) | 20 (19) | 0.824 |
GOLD stage | | | |
A B C D | 11 (15) 45 (61) 0 (0) 18 (24) | 22 (21) 53 (50) 4 (4) 27 (26) | 0.206 |
Yearly exacerbations | 21 (28) | 40 (38) | 0.197 |
≥2 moderate/severe AECOPD/year, n (%) | 18 (24) | 20 (19e) | 0.377 |
Atopy | 14 (19) | 18 (17) | 0.864 |
CT sinus score (n=57) | 1.5 (0–2.25) | 1 (0–2.5) | 0.574 |
CT sinus score ≥1 | 15 (71) | 20 (56) | 0.235 |